

Formulation informed brief acceptance and commitment therapy for functional neurological disorder

Submission date 18/08/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 12/09/2023	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 11/09/2023	Condition category Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Functional Neurological Disorder (FND) is a problem with the functioning of the nervous system and how the brain and body send and receive signals. FND has multiple causes that can vary from patient to patient. Each individual with FND can have different combinations and severity of symptoms, including problems with movement, senses and episodes of altered awareness, like seizures and blackouts. Individuals with this condition have long delays in receiving a diagnosis. This can stop individuals from developing an understanding of their condition and accessing appropriate psychological services.

Information from up-to-date research shows that a formulation, or explanation of an individual's condition, can improve people's quality of life and even reduce how often they experience the symptoms. Acceptance and Commitment Therapy (ACT) has been shown to also improve quality of life, mood and how symptoms affect the person. This therapy aims to help people to live well despite the difficulties they are experiencing. Currently, there is some promising evidence that ACT can help people with FND live a better life, but more research is needed. So far, no one has completed research that explores if formulation and ACT together can be helpful for people who have FND. This study is investigating if formulation and ACT-based intervention can lead to increases in psychological health, emotional processing and quality of life. While ACT does not directly aim to get rid of illness symptoms, such as seizures, the researchers want to see if symptoms may reduce anyway.

Who can participate?

Adults (18 years of age and over) with a formal diagnosis of Functional Neurological Disorder

What does the study involve?

It will require active participation for 13 weeks. During this time participants will be asked to complete some questionnaires and attend psychotherapy sessions at a local clinic. The study will involve five sessions and will require participants to answer some brief questions every other day throughout this period. After 11 weeks, participants will be contacted again a month later.

What are the possible benefits and risks of participating?

There may be no benefit to taking part in this study. However, the benefits may relate to developing a better understanding condition and developing some new coping strategies. When engaging in any psychological therapy, people may experience some psychological discomfort or distress. We are not anticipating any additional risk and no higher risk than that of standard medical care.

Where is the study run from?

Dorset Healthcare University NHS Foundation Trust (UK)

When is the study starting and how long will it run for?

November 2021 to July 2023

Who is funding the study?

University of Southampton (UK)

Who is the main contact?

1. Irma Konovalova, ik1n20@soton.ac.uk

2. Dr Warren Dunger

Contact information

Type(s)

Public

Contact name

Miss Irma Konovalova

Contact details

University of Southampton

Highfield Campus

Southampton

United Kingdom

SO17 1BJ

N/A

I.Konovalova@soton.ac.uk

Additional identifiers

Integrated Research Application System (IRAS)

311583

Study information

Scientific Title

Effectiveness and acceptability of formulation and Brief-ACT intervention for functional neurological disorder

Study objectives

The primary objectives were to establish the effect of a Formulation Informed Brief Acceptance and Commitment Therapy (F-ACT) intervention on symptom interference, measured as distress and impact on engagement in daily activities, and psychological health, emotional processing, quality of life, psychological inflexibility and understanding of functional neurological disorder (FND).

The secondary objective was to examine if the intervention benefits FND illness symptom reduction, specific to patient presentation.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 04/11/2022, North West - Greater Manchester Central Research Ethics Committee (3rd Floor Barlow House, 4 Minshull Street, Manchester, M1 3DZ, United Kingdom; +44 (0)207 104 8057, +44 (0)207 104 8244, +44 (0)207 104 8004; gmcentral.rec@hra.nhs.uk), ref: 22/NW/0320

Study design

Single-case experimental design

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Functional neurological disorder (FND)

Interventions

The intervention consisted of two parts. The first part included the development of a collaborative biopsychosocial formulation with the participant, to help them gain a better understanding of their illness, following a clinical interview. The second included three Acceptance and Commitment Therapy (ACT) sessions, based on three functional units (Triflex) that aim to increase psychological flexibility.

The study will require active participation for 13 weeks. During this time participants will be asked to complete some questionnaires and attend psychotherapy sessions at a local clinic. The study will involve five sessions and will require participants to answer some brief questions every other day throughout this period. After 11 weeks, participants will be contacted again 1 month later.

Intervention Type

Behavioural

Primary outcome(s)

The following questionnaires were completed at baseline, following the formulation intervention, following the ACT-based intervention and at the end of the follow-up period:

1. Quality of life (QoL) measured using the Work and Social Adjustment Scale (WSAS)
2. Emotional processing measured using the Emotional Processing Scale (EPS)
3. Psychological health measured using a 34-item Clinical Outcomes in Routine Evaluation –

Outcome Measure (CORE-OM)

4. Psychological inflexibility measured using the Acceptance and Action Questionnaire (AAQ-II)
5. Illness perception and understanding of the condition measured using the Brief Illness Perception Questionnaire (BIPQ)

Key secondary outcome(s)

Symptom frequency was measured by a self-rated question "Over the last few days: (1) how often have you experienced the symptoms of your illness". It was rated on a 10-point Likert scale ranging from 0 (no symptoms) to 10 (many severe symptoms). It was completed every 2 days throughout the length of the study.

Completion date

04/07/2023

Eligibility

Key inclusion criteria

1. Adults aged 18 years and above
2. Capable of giving informed consent
3. FND diagnosis confirmed by a neurologist
4. Sufficient English to engage in therapy
5. Not currently engaged in another psychotherapy or FND treatment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

6

Key exclusion criteria

1. Primary diagnosis of intellectual disability
2. Severe mental ill health requiring inpatient treatment or potentially affecting trial participation (e.g., suicidality, acute psychosis, active or extensive self-harm)
3. A diagnosis of a complex regional pain syndrome, dissociative identity disorder, or posttraumatic stress disorder of high severity with significant dissociation

Date of first enrolment

07/11/2022

Date of final enrolment

31/03/2023

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Dorset Healthcare University NHS Foundation Trust

Sentinel House

4-6 Nuffield Road

Nuffield Industrial Estate

Poole

United Kingdom

BH17 0RB

Sponsor information

Organisation

University of Southampton

ROR

<https://ror.org/01ryk1543>

Funder(s)

Funder type

University/education

Funder Name

University of Southampton

Alternative Name(s)

University of Southampton UK

Funding Body Type

Government organisation

Funding Body Subtype

Universities (academic only)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date